Inverse relationship between proliferation and differentiation in a human TNP-specific B cell line. Cell cycle dependence of antibody secretion.
Studies of an EBV-transformed and TNP-specific human B cell line revealed that, unlike myeloma or hybridoma cell lines that consist mainly of fully differentiated cells, most of the cloned EBV-transformed cells were not fully differentiated, as judged by inability to bind TNP-SRBC and to secrete anti-TNP antibody. The minority of more differentiated cells were selected by TNP-SRBC rosetting. They were found to proliferate to a lesser extent than nonrosetting cells and to contain increased numbers of antibody-secreting cells. This inverse relationship between proliferation and differentiation was also shown to be cell cycle related in that the TNP-SRBC rosetting cells resided, to a greater extent than the nonrosetting cells, in the G1 phase of the cell cycle. The finding that the G1 phase of the cell cycle was associated with differentiation into anti-TNP secreting cells was confirmed by demonstrating that treatment with hydroxyurea, which arrests the cells in G1, resulted in decreased proliferation and an increased proportion of antibody-secreting cells. Similarly, addition of phorbol ester resulted in increased antibody secretion and decreased proliferation, suggesting a role for protein kinase C in this differentiation pathway. The strategy of increasing the number of antibody-producing cells in this human EBV line, by promoting differentiation of the cells in G1, may be relevant to the large scale production of specific human mAb for the treatment and diagnosis of human diseases.
Golding
B
B
Division of Blood and Blood Products, U.S. Food & Drug Administration, Bethesda, MD.
Pillemer
S R
SR
Roussou
P
P
Peters
E A
EA
Tsokos
G C
GC
Ballow
J E
JE
Hoffman
T
T
D000917:Antibody Formation; D000921:Antibody-Producing Cells / Q000145:classification; D001402:B-Lymphocytes / Q000145:classification / Q000166:cytology / Q000276:immunology*; D002453:Cell Cycle / Q000187:drug effects; D002454:Cell Differentiation / Q000187:drug effects; D002460:Cell Line; D000939:Epitopes / Q000276:immunology; D006801:Humans; D006918:Hydroxyurea / Q000494:pharmacology; D007399:Interphase / Q000187:drug effects; D007958:Leukocyte Count / Q000187:drug effects; D008213:Lymphocyte Activation / Q000187:drug effects; D009578:Nitrobenzenes / Q000276:immunology*; D013234:Stem Cells / Q000145:classification; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D014301:Trinitrobenzenes / Q000276:immunology*
D000939:Epitopes; D009578:Nitrobenzenes; D014301:Trinitrobenzenes; D013755:Tetradecanoylphorbol Acetate; D006918:Hydroxyurea